Non-motor symptoms in Chinese Parkinson’s disease patients with and without LRRK2 G2385R and R1628P variants

Journal of Neural Transmission

Volumn 122, Issue 5, 2015, Pages 661-667

  Li, Da Wei ^a   Gu, Zhuqin ^a,b   Wang, Chaodong ^a,b   Ma, Jinghong ^a,b   Tang, Bei Sha ^c   Chen, Sheng Di ^d   Chan, Piu ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

LRRK2 variants; NMSQuest; Nocturia; Non motor symptoms; Parkinson s disease

Indexed keywords

ANTIPARASITIC AGENT; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME;

AGE FACTORS; ANTIPARASITIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 84939887116     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1281-4     Document Type: Article

References (34)

1. Bardien S, Lesage S, Brice A et al (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 17:501–508
2. Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649
3. Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006a) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923
4. Chaudhuri KR, Healy DG, Schapira AH (2006b) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245
5. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704–709
6. Chen W, Xu ZM, Wang G et al (2012) Non-motor symptoms of Parkinson’s disease in China: a review of the literature. Parkinsonism Relat Disord 18:446–452
7. Cornu JN, Abrams P, Chapple CR et al (2012) A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. Eur Urol 62:877–890
8. Correia Guedes L, Ferreira JJ, Rosa MM et al (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 16:237–242
9. Farrer MJ, Stone JT, Lin CH et al (2007) LRRK2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 13:89–92
10. Gaig C, Marti MJ, Ezquerra M et al (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78:626–628
11. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
12. Healy DG, Falchi M, O’Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7:583–590
13. Huang Y, Halliday GM, Vandebona H et al (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson’s disease. Mov Disord 22:982–989
14. Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
15. Khoo TK, Yarnall AJ, Duncan GW et al (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281
16. Litvan I, Bhatia KP, Burn DJ et al (2003) Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467–486
17. Lu CS, Wu-Chou YH, van Doeselaar M et al (2008) The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population. Neurogenetics 9:271–276
18. Mariappan P, Turner KJ, Sothilingam S et al (2007) Nocturia, nocturia indices and variables from frequency-volume charts are significantly different in Asian and Caucasian men with lower urinary tract symptoms: a prospective comparison study. BJU Int 100:332–336
19. Marras C, Schule B, Munhoz RP et al (2011) Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77:325–333
20. Marti-Masso JF, Ruiz-Martinez J, Bolano MJ et al (2009) Neuropathology of Parkinson’s disease with the R1441G mutation in LRRK2. Mov Disord 24:1998–2001
21. Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629
22. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM et al (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26:399–406
23. Romenets SR, Wolfson C, Galatas C et al (2012) Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord 18:54–58
24. Ross OA, Wu YR, Lee MC et al (2008) Analysis of LRRK2 R1628P as a risk factor for Parkinson’s disease. Ann Neurol 64:88–92
25. Silveira-Moriyama L, Guedes LC, Kingsbury A et al (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 71:1021–1026
26. Tanaka K, Miyake Y, Fukushima W et al (2011) Intake of Japanese and Chinese teas reduces risk of Parkinson’s disease. Parkinsonism Relat Disord 17:446–450
27. Tanner CM, Aston DA (2000) Epidemiology of Parkinson’s disease and akinetic syndromes. Curr Opin Neurol 13:427–430
28. Tykocki T, Kornakiewicz A, Mandat T et al (2013) Pain perception in patients with Parkinson’s disease. J Clin Neurosci 20:663–666
29. Valldeoriola F, Gaig C, Muxi A et al (2011) 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. J Neurol 258:1126–1132
30. Varilla V, Samala RV, Galindo D et al (2011) Nocturia in the elderly: a wake-up call. Cleve Clin J Med 78:757–764
31. Wang G, Cheng Q, Zheng R et al (2006) Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 21:1439–1443
32. Wang G, Hong Z, Cheng Q et al (2009) Validation of the Chinese non-motor symptoms scale for Parkinson’s disease: results from a Chinese pilot study. Clin Neurol Neurosurg 111:523–526
33. Wang C, Cai Y, Zheng Z et al (2012) Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord 18:958–963
34. Yu B, Xiao ZY, Li JZ et al (2010) Study of an integrated non-motor symptoms questionnaire for Parkinson’s disease. Chin Med J (Engl) 123:1436–1440